SPOC Medical
Stamford
About SPOC Medical
SPOC Medical is a medical device venture focused on transforming how chronic pain is diagnosed and treated. Co-founded with an NYU physician, the company patented (USPTO #7,826,900) and commercialized the Muscle Pain Detection Device (MPDD)’a Class II medical device that precisely locates muscle-based pain often missed by traditional imaging. By bringing objective diagnosis to a $6B+ annual soft-tissue pain market, SPOC Medical aimed to improve patient outcomes while reducing unnecessary surgeries and healthcare costs. Key Highlights • Product Innovation: The MPDD uses gentle electrical stimulation to identify specific muscles responsible for chronic pain, guiding targeted therapies that help patients avoid invasive procedures and lengthy treatment cycles. • Regulatory Milestone: Achieved FDA 510(k) clearance and design transfer within three years, validating the MPDD’s clinical safety and efficacy. • Clinical Validation: • A 90-patient trial at NYU Medical Center confirmed the device’s safety and alignment with electrical-stimulation research by Dr. Norman Marcus. • A 40-patient randomized controlled study demonstrated significantly better pain relief (82.5% vs. 53.2%) and improvements in mood and function for MPDD users compared to controls (P < 0.05). • Multiple peer-reviewed publications, including Pain Medicine, further validated the technology. • Funding: Secured $1M across two rounds, including $800K from Connecticut Innovations’ BioSeed Fund, to advance device development and clinical trials. • Market Impact: • U.S. direct costs for lower back pain exceed $50–66B annually, while indirect costs can top $100–200B. The MPDD addresses this massive economic burden by targeting and relieving the muscular source of pain. • Globally, musculoskeletal pain imposes hundreds of billions of dollars in direct and indirect costs, fueling demand for effective diagnostic tools. • Media Recognition: Featured on national outlets, such as NBC’s Today Show, ABC’s Good Morning America, and Fox News*, as well as publications like Fortune, Medical News Today, and Slate. • Commercial Outcome: Following successful clinical outcomes and media coverage, SPOC’s assets were acquired in 2012, marking a successful exit for investors and stakeholders. By tackling the root cause of musculoskeletal pain, SPOC Medical’s MPDD provided a promising solution to an often overlooked yet widespread problem. Through evidence-based research, regulatory milestones, and strong market uptake, SPOC Medical established itself as a transformative player in pain-management technology before its eventual acquisition.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $1.0M
- Funding stage: M&A
- Last round: Seed (Jun 2007)
- Website: spocmedical.com
- Phone: [email protected]
Industries & Categories
Health Care, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/spoc-medical-2112746 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.